[Organ protection by angiotensin II receptor blockers].
Kumagai
Hiroo
H
Department of Internal Medicine, Keio University School of Medicine.
Onami
Toshiko
T
Takimoto
Chie
C
Iigaya
Kamon
K
Saruta
Takao
T
D000804:Angiotensin II / Q000502:physiology; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D003072:Cognition Disorders / Q000209:etiology / Q000517:prevention & control*; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007674:Kidney Diseases / Q000209:etiology / Q000517:prevention & control*; D019808:Losartan / Q000494:pharmacology / Q000627:therapeutic use*; D008565:Membrane Proteins; D000451:Mineralocorticoid Receptor Antagonists; D011506:Proteins / Q000378:metabolism; D011507:Proteinuria / Q000209:etiology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D008565:Membrane Proteins; D000451:Mineralocorticoid Receptor Antagonists; D011506:Proteins; D013777:Tetrazoles; C113267:nephrin; D000804:Angiotensin II; D019808:Losartan; C081643:candesartan